Best Peptides For, homeEvidence guides, by goal

Home / Editorial policy

Editorial policy

Last updated

What “best” means. Best means the strongest published evidence that a peptide helps with a goal. It doesn’t mean safe, and it doesn’t mean right for you. We rank by the type of evidence first, then its quality and its result. A rank isn’t a recommendation. If no peptide has good evidence for a goal, we say so.

Types of evidence.

What our labels mean.

Sources and checks. Every factual claim links to its source. We prioritize FDA, PubMed, ClinicalTrials.gov, peer-reviewed journals and primary press releases. When we rely on a secondary source, we link to it. Each guide is checked against its cited sources before it’s published. U.S. regulatory status is checked on the day of publication, and the date appears on the page. Status can change after that date.

What we don’t publish. We don’t publish doses, cycles or mixing instructions for unapproved peptides. For approved medicines, we point to the FDA label and a clinician. We don’t promise cures or results, and we don’t publish before-and-after claims. We don’t link to or recommend “research use only” or gray-market sellers for human use.

Who writes this. Guides carry the byline of the Best Peptides For Editorial Team. We use AI tools to help research, write and check our pages. A “Reviewed by” line appears only when a named person actually reviewed the page, with the date.

Corrections. When we find an error, we correct the guide in place, update its date and list it on our corrections page.

Commercial relationships. Any commercial relationship is disclosed clearly, next to the content it touches.